Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED) [1][6] - The company's ordinary shares are listed on the NASDAQ Capital Market [6] - OKYO Pharma is currently evaluating its lead program, OK-101, in Phase 2 trials for both NCP and DED [5][6] Funding and Financials - OKYO Pharma has received $1.4 million in non-dilutive funding, which will be used to advance its research and development initiatives [1][2] - The funding is strategically allocated to support the company's lead program, OK-101, particularly for the treatment of NCP [2] - This financial boost strengthens the company's ability to advance its innovative pipeline without diluting shareholder value [1][3] Product Pipeline - OK-101 is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled receptor, found on immune cells, neurons, and glial cells in the eye [5] - The drug candidate has shown anti-inflammatory and pain-reducing activities in mouse models of DED and NCP [5] - OK-101 has demonstrated clear statistical significance in multiple endpoints in a Phase 2 trial for DED and is currently being evaluated in a Phase 2 trial for NCP [5][6] Market and Medical Need - NCP is a severe ocular condition without an FDA-approved therapy, currently treated with off-label topical and systemic treatments [4] - DED represents a multi-billion-dollar market, highlighting the significant commercial potential for OKYO Pharma's therapies [1] - The company is addressing critical unmet medical needs in ophthalmology, particularly for patients suffering from chronic and debilitating conditions [4][5] Leadership and Contact Information - Dr Gary S Jacob serves as the CEO of OKYO Pharma [3] - For business development and investor relations, Paul Spencer can be contacted at +44 (0)20 7495 2379 [8]

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinibSAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). ...

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1 to 5.9, p<0.001) at week 14-- NEWTOWN, Pa., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Hel ...

REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it was awarded a contract with an international organization for the supply of KAMRAB® and VARIZIG® in Latin America for 2025-2027. Total expected revenue under the three-year contract for both products is estima ...

Thomasville, Ga, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Flowers Foods to Report Fourth Quarter and Full Year 2024 Results Flowers Foods, Inc. (NYSE: FLO) will report its fourth quarter and full year 2024 financial results on Friday, February 7, 2025, at 7:00 a.m. Eastern Time. The company will host a live question and answer webcast at 8:30 a.m. Eastern Time the same day. Access to the webcast, along with the press release, pre-recorded remarks by management with accompanying transcript, and supporting slide p ...

BOCA RATON, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), the most trusted brand in smart home and small business security, today announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. “We are pleased to welcome Tom to our board of directors,” said ADT Chairman, President and CEO, Jim DeVries. “Tom’s proven track record of driving operational e ...

Company Leadership - Lantronix Inc's president and CEO, Saleel Awsare, has been appointed to the Forbes Technology Council, an exclusive community for global business and technology leaders [1] - Awsare was selected based on his achievements, thought leadership in the technology industry, and proven track record of success in leadership roles [1] - Awsare has led transformational changes across IoT, mobile, communications, wireless, and related industries during his tenure at multiple companies, including Lantronix, Synaptics Inc, Conexant Systems LLC, and Nuvoton Technology Corporation [2] CEO's Background and Achievements - Prior to joining Lantronix in 2023, Awsare served as senior vice president and general manager of Synaptics Inc's Enterprise and Mobile Division, its largest division [3] - Awsare played a key role in Synaptics' pivot from mobile to IoT and enterprise markets, which significantly increased the company's market valuation [3] - From 2012 to 2017, Awsare served as president of Conexant Systems LLC, where he positioned the company as a market leader in audio and voice technologies, contributing to its successful acquisition by Synaptics in 2017 [4] - From 2008 to 2012, Awsare was president of Nuvoton Technology Corporation America, responsible for US-based operations [4] Company Overview - Lantronix Inc is a global leader in compute and connectivity IoT solutions, targeting high-growth industries such as Smart Cities, Automotive, and Enterprise [6] - The company's products and services enable companies to succeed in IoT markets by delivering customizable solutions addressing each layer of the IoT Stack [6] - Lantronix's leading-edge solutions include Intelligent Substations infrastructure, Infotainment systems, Video Surveillance, and advanced Out-of-Band Management (OOBM) for Cloud and Edge Computing [6] Industry Focus - The company is focused on AI and IoT transformations that are shaping how enterprises conduct business globally [2] - Lantronix works with leading enterprises as they embrace digital transformation and enter a new era of edge intelligence, supported by the company's cutting-edge solutions and engineering expertise [2]

CHICAGO, MILWAUKEE and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- YieldMax™ today announced distributions for the YieldMax™ ETFs listed in the table below. ETF Ticker1ETF NameReference AssetDistribution per Share2Distribution FrequencyEx-Date & Record DatePayment DateLFGYYieldMax™ Crypto Industry & Tech Portfolio Income ETF<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: sol ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Air Transport Services Group, Inc. (NASDAQ: ATSG)’s sale to Stonepeak for $22.50 per share in cash. If you are an Air Transport shareholder, click here to learn more about your legal rights and options. Retail Opportunity Investments Corp. (NASDAQ: ROIC)’s sa ...

Understand the significant growth trajectory of the Conveyors segment, which is expected to reach US$9.2 Billion by 2030 with a CAGR of a 5.7%. The Destination Coded Vehicles segment is also set to grow at 6.9% CAGR over the analysis period. Gain insights into the U.S. market, estimated at $2.2 Billion in 2023, and China, forecasted to grow at an impressive 8.2% CAGR to reach $2.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Airport Ba ...